320.05

1.10% -3.57

After Hours: 320.05

United Therapeutics Corp (UTHR)

Overview News Price History Option Chain Financials Why UTHR Down? Discussions Forecast Stock Split

United Therapeutics Corp stock is traded at $320.05, with a volume of 629.33K. It is down -1.10% in the last 24 hours and down -8.86% over the past month. United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Previous Close:

$323.62

Open:

$324.06

24h Volume:

629.33K

Relative Volume:

1.78

Market Cap:

$14.37B

Revenue:

$2.76B

Net Income/Loss:

$1.11B

P/E Ratio:

14.06

EPS:

22.77

Net Cash Flow:

$898.10M

1W Performance:

-11.37%

1M Performance:

-8.86%

6M Performance:

-11.97%

1Y Performance:

+41.84%

1-Day Range:

$313.66

$324.06

1-Week Range:

$307.38

$365.21

52-Week Range:

$221.53

$417.81

United Therapeutics Corp Stock (UTHR) Company Profile

Name

United Therapeutics Corp

Sector

Healthcare (1168)

Industry

Biotechnology (679)

Phone

(301) 608-9292

Address

1000 SPRING ST, SILVER SPRING, MD

Employee

1,305

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

UTHR's Discussions on Twitter

Compare UTHR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
UTHR United Therapeutics Corp	320.05	14.37B	2.76B	1.11B	898.10M	22.77
VRTX Vertex Pharmaceuticals Inc	479.79	123.21B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	698.74	76.39B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	624.67	37.96B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	246.75	31.94B	2.25B	-278.16M	-42.59M	-2.17
ONC Beone Medicines Ltd Adr	271.80	29.00B	3.32B	-860.46M	-1.04B	-8.32

United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-11-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-12-24	Upgrade	Goldman	Sell → Neutral
Feb-05-24	Initiated	Leerink Partners	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Dec-06-22	Initiated	UBS	Buy
Dec-05-22	Initiated	Goldman	Sell
Oct-11-22	Initiated	Morgan Stanley	Overweight
Sep-20-22	Reiterated	BofA Securities	Underperform
Sep-19-22	Resumed	Wedbush	Outperform
Feb-11-22	Initiated	BTIG Research	Neutral
Jul-14-21	Upgrade	Argus	Hold → Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Feb-01-21	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-14-20	Resumed	JP Morgan	Overweight
Jun-25-20	Reiterated	H.C. Wainwright	Neutral
Mar-10-20	Upgrade	Jefferies	Hold → Buy
Feb-27-20	Upgrade	Cowen	Market Perform → Outperform
Jan-31-20	Upgrade	JP Morgan	Neutral → Overweight
Dec-03-19	Initiated	BofA/Merrill	Underperform
Aug-01-19	Upgrade	Jefferies	Underperform → Hold
Aug-01-19	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jul-01-19	Upgrade	Credit Suisse	Neutral → Outperform
May-17-19	Upgrade	UBS	Sell → Neutral
May-09-19	Upgrade	Credit Suisse	Underperform → Neutral
Oct-12-18	Upgrade	Standpoint Research	Hold → Buy
Aug-08-18	Downgrade	Credit Suisse	Neutral → Underperform
Apr-03-18	Upgrade	Credit Suisse	Underperform → Neutral
Feb-22-18	Reiterated	Barclays	Underweight
Jan-18-18	Resumed	Credit Suisse	Underperform
Dec-27-17	Reiterated	Wedbush	Outperform
Apr-27-17	Reiterated	Wedbush	Outperform
Mar-30-17	Initiated	UBS	Sell
Mar-16-17	Initiated	Credit Suisse	Underperform

View All

United Therapeutics Corp Stock (UTHR) Latest News

Mar 01, 2025

Oppenheimer Asset Management Inc. Sells 6,988 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Mar 01, 2025

Bank of New York Mellon Corp Sells 1,693 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Mar 01, 2025

United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by New York State Common Retirement Fund - MarketBeat

Mar 01, 2025

Feb 28, 2025

Weil Company Inc. Has $449,000 Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Feb 28, 2025

United Therapeutics (NASDAQ:UTHR) Releases Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat

Feb 28, 2025

United Therapeutics (NASDAQ:UTHR) Shares Gap Down Following Insider Selling - MarketBeat

Feb 28, 2025

United Therapeutics Co. (NASDAQ:UTHR) Stock Position Boosted by Fjarde AP Fonden Fourth Swedish National Pension Fund - MarketBeat

Feb 28, 2025

United Therapeutics (NASDAQ:UTHR) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat

Feb 28, 2025

Los Angeles Capital Management LLC Has $36.55 Million Stake in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Feb 28, 2025

Truist Financial Corp Sells 2,920 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Feb 28, 2025

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz Sells 10,000 Shares - MarketBeat

Feb 28, 2025

Feb 27, 2025

United Therapeutics Corp. Reports Record Revenue and Growth - TipRanks

Feb 27, 2025

United Therapeutics Corp. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025

United Therapeutics Reports Record Revenue in Q4 2024, Advances Strategic Growth - HPBL

Feb 27, 2025

United Therapeutics Corporation (NASDAQ:UTHR) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 27, 2025

Goldman Sachs cuts United Therapeutics stock target to $293 By Investing.com - Investing.com Australia

Feb 27, 2025

Goldman Sachs cuts United Therapeutics stock target to $293 - Investing.com

Feb 27, 2025

United Therapeutics: Q4 Earnings Snapshot - Thehour.com

Feb 27, 2025